| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
tobacco mosaic virus[2]
Rubinaphthin A exhibits inhibitory activity against tobacco mosaic virus (TMV). As a natural naphthohydroquinone, it targets viral replication mechanisms, though its specific molecular target has not been fully characterized. The compound is believed to interfere with viral infection processes, potentially by disrupting viral coat protein assembly or inhibiting viral RNA synthesis in plant cells. |
|---|---|
| ln Vitro |
Compound C, also known as rubinaphthin A, has 51.49% inhibition rate against TMV at 200 μg/mL.
In vitro studies have demonstrated that Rubinaphthin A at a concentration of 200 microg/mL shows inhibitory activity against tobacco mosaic virus (TMV), with an inhibition rate of 51.49%. This antiviral activity suggests potential for agricultural applications in controlling plant viral diseases. No mammalian cell-based activity has been reported for this natural product. |
| ln Vivo |
No specific in vivo activity data is available for Rubinaphthin A in animal models. The reported in vivo antiviral activity is based on plant-based assays against TMV infection in plant hosts. Further studies in mammalian systems would be required to evaluate potential systemic effects. Research on related naphthohydroquinone compounds suggests potential antioxidant and anti-inflammatory activities.
|
| Enzyme Assay |
No specific protocol is available for this natural product. For typical enzyme or binding studies: Dissolve Rubinaphthin A in DMSO to prepare stock solutions (10-50 mM). For binding assays, dilute to working concentrations (0.1-100 microM) in appropriate assay buffer. Incubate with purified target proteins or viral components. Measure binding affinity using surface plasmon resonance or fluorescence-based methods. Include appropriate controls to validate specificity.
|
| Cell Assay |
For antiviral assays against plant viruses: Prepare Rubinaphthin A solutions in DMSO and dilute with water containing appropriate surfactants to achieve final concentrations of 10-500 microg/mL. Apply the compound solution to plant leaves prior to or after virus inoculation. Incubate for 24-48 hours. Measure viral inhibition by quantifying viral RNA levels or observing disease symptoms compared to untreated infected controls. Use standard greenhouse conditions for plant maintenance.
|
| Animal Protocol |
No specific animal protocol exists for this natural compound as research has primarily focused on plant viral models. For potential in vivo studies in animal models: Dissolve the compound in DMSO followed by dilution in 5% DMSO + 30% PEG300 + 5% Tween 80 + 60% saline. Administer intraperitoneally or orally at doses ranging from 10-100 mg/kg. Monitor for efficacy in disease models and assess tissue distribution.
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data is available for Rubinaphthin A in mammalian systems. As a natural naphthohydroquinone with a molecular weight of 366.32 g/mol, it is expected to have moderate oral bioavailability and may undergo phase II metabolism. The compound should be stored at -20degC. For obtaining higher solubility, warm the tube to 37degC and shake in an ultrasonic bath before use.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is available for Rubinaphthin A. As a natural product isolated from a medicinal plant, it is presumed to have moderate safety profile, but comprehensive toxicological studies have not been performed. Standard laboratory safety practices should be followed when handling this compound. Avoid inhalation and skin contact. Use appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
Reports indicate that madder root from Yunnan contains alizarin A, and relevant data is available for reference.
Rubinaphthin A is a research-grade natural product supplied as a lyophilized powder. It is recommended to store the compound at -20degC in a dark, dry environment to maintain stability. The compound is soluble in DMSO (10-50 mM) and ethanol, but has poor solubility in water. It is intended for biochemical research only, not for clinical use. No clinical trials or approved status exist. |
| Molecular Formula |
C17H18O9
|
|---|---|
| Molecular Weight |
366.32
|
| Exact Mass |
366.095
|
| CAS # |
448962-05-8
|
| PubChem CID |
11760306
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
688.2±55.0 °C at 760 mmHg
|
| Flash Point |
253.5±25.0 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.732
|
| LogP |
0.71
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
501
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C1=CC=C2C(=C1)C(=CC(=C2O)C(=O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O
|
| InChi Key |
SGTNXGSCHXKQJX-OQAPJDJNSA-N
|
| InChi Code |
InChI=1S/C17H18O9/c18-6-11-13(20)14(21)15(22)17(26-11)25-10-5-9(16(23)24)12(19)8-4-2-1-3-7(8)10/h1-5,11,13-15,17-22H,6H2,(H,23,24)/t11-,13-,14+,15-,17-/m1/s1
|
| Chemical Name |
1-hydroxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynaphthalene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7299 mL | 13.6493 mL | 27.2985 mL | |
| 5 mM | 0.5460 mL | 2.7299 mL | 5.4597 mL | |
| 10 mM | 0.2730 mL | 1.3649 mL | 2.7299 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
